Remepy
Biotechnology · Health Care

Remepy news and milestones

Remepy: 40 headlines on record, 4 headlines in the last 90 days. Its story counts 4 milestones.

Data updated Nov 17, 2026 · Back to the company report
40Headlines
4In 90 days
4Milestones

Headlines

Sep 292026
News · neurology live
Hybridopa improved MDS-UPDRS scores in a small phase 2a Parkinson disease trial, with phase 3 testing planned for 2026.
Sep 162026
Press release · PRNewswire
/PRNewswire/ -- Remepy, the pioneer of Hybrid Drugs, today announced the appointment of Eran Harary, MD, as Chief Medical Officer, effective October 1, 2026....
Sep 162026
Aug 202026
News · Pulse 2.0
Remepy has raised $36 million in Series A financing to advance its pipeline of Hybrid Drugs, including global Phase III development of Hybridopa for Parkinson's disease, bringing…
Aug 132026
News · Tech Lens Media
Remepy raised $36M to advance Hybridopa into Phase III and expand its Hybrid Drug platform combining medicines with personalized AI-driven digital protocols.
Aug 132026
News · Pharmaceutical Technology
Remepy has secured $36m in Series A funds to accelerate its pharmaceutical co-development partnerships and expand its hybrid drug pipeline.
Aug 122026
News · Pulse 2.0
Remepy has raised $36 million in Series A funding to expand its Hybrid Drug pipeline, accelerate pharmaceutical partnerships, and fund global Phase III development of Hybridopa f…
Aug 122026
Press release · PRNewswire
/PRNewswire/ -- Remepy, the pioneer of Hybrid Drugs, today announced the closing of a $36 million Series A financing round led by O.G. Venture Partners and M...
Aug 122026
News · jewishbreakingnews.com
Jul 12026
News · BriefGlance
New imaging data provides the first evidence that a drug-app combo for Parkinson's can induce physical changes in the brain, linking digital therapy to ...
Jun 262026
News · Nature
Diffusion tensor imaging (DTI) is a sensitive method for detecting white-matter alterations in Parkinson's disease (PD) and is increasingly used to capture short-term learning-in…
Jun 92026
News · Drug Discovery and Development
Remepy's Hybridopa pairs carbidopa-levodopa with an AI-driven app and cleared a Phase IIa Parkinson's trial, nearly doubling the drug's effect on the MDS-UPDRS.
May 212026
News · Yahoo News
Levodopa plus Remepy's digital health app, DopApp, offered significant activities of daily living and motor function benefits.
May 212026
News · pharmaphorum
Remepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.
Apr 282026
News · YahooFinance
The pair will develop drug-digital therapeutic combinations as a singular product, thus sidestepping reimbursement hurdles linked to individually approved digital therapies.
Jun 14, 20252025
News · Nature
Subjective cognitive decline (SCD) is a potential early marker of neurodegeneration, with negative affective states such as depression and anxiety significantly contributing to c…
Feb 26, 20252025
News · Nature
Late-life depression represents a significant health concern, linked to disruptions in brain connectivity and immune functioning, mood regulation, and cognitive function. This pi…
Feb 14, 20242024
News · Globes
Former Israeli Prime Minister Naftali Bennett has joined the board of Remepy, which is pioneering hybrid drugs that include therapeutic applications that enhance the drug effect.
News · academic.oup.com
Hybrid Drugs are a new class of drugs that combine prescription medicines with personalized, AI-driven therapeutic apps, integrating pharmacology with adaptive physical, cognitiv…
Sources: the outlets named on each headline, each story once

Milestones

Each milestone is dated by its source: registers, filings, the press

How to cite

Remepy, News. Alion, Nov 17, 2026. https://alion.io/company/remepy/news

.json · .md · CC BY-SA 4.0